AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
IPO Year: 2005
Exchange: NASDAQ
Website: atricure.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2026 | Outperform → Perform | Oppenheimer | |
| 2/11/2026 | $36.00 | Overweight → Neutral | Analyst |
| 12/17/2024 | $40.00 | Overweight | Analyst |
| 4/23/2024 | $32.00 | Perform → Outperform | Oppenheimer |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/29/2023 | $56.00 | Buy | UBS |
| 2/16/2022 | $120.00 → $88.00 | Buy | Canaccord Genuity |
| 2/16/2022 | $92.00 → $79.00 | Buy | Needham |
| 11/4/2021 | $90.00 → $92.00 | Buy | Needham |
| 11/4/2021 | $100.00 → $110.00 | Outperform | SVB Leerink |
Fastest customizable press release news feed in the world
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related c
First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, EnCompass® clamp, and AtriClip PRO-Mini® AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. "Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined exe
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, May 12, 2026, at 10:00 a.m. Pacific Daylight Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related cond
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricur
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more tha
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic re-rating is driven by healthcare's structural pivot from bulky, expensive hardware to agile, software-defined intelligence. As diagnostics move out of specialized labs and into decentralized, point-of-care environments[2], institutions are rotating capital into a first-mover cohort capable of delivering MRI-grade accuracy on the fly. This secular transition is positioning VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Heartflow (NASDAQ:HTFL), AtriCure (NASDAQ:ATRC), Edwards
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 14, 2026, at 10:30 a.m. Pacific Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more tha
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - AtriCure, Inc. (0001323885) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
SD - AtriCure, Inc. (0001323885) (Filer)
8-K - AtriCure, Inc. (0001323885) (Filer)
SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
10-Q - AtriCure, Inc. (0001323885) (Filer)
8-K/A - AtriCure, Inc. (0001323885) (Filer)
8-K - AtriCure, Inc. (0001323885) (Filer)
DEFA14A - AtriCure, Inc. (0001323885) (Filer)
DEF 14A - AtriCure, Inc. (0001323885) (Filer)
SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)
10-K - AtriCure, Inc. (0001323885) (Filer)
Oppenheimer downgraded AtriCure from Outperform to Perform
Analyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00
Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00
Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00
JMP Securities initiated coverage of AtriCure with a rating of Mkt Outperform and set a new price target of $60.00
UBS initiated coverage of AtriCure with a rating of Buy and set a new price target of $56.00
Canaccord Genuity reiterated coverage of AtriCure with a rating of Buy and set a new price target of $88.00 from $120.00 previously
Needham reiterated coverage of AtriCure with a rating of Buy and set a new price target of $79.00 from $92.00 previously
Needham reiterated coverage of AtriCure with a rating of Buy and set a new price target of $92.00 from $90.00 previously
SVB Leerink reiterated coverage of AtriCure with a rating of Outperform and set a new price target of $110.00 from $100.00 previously
Live Leadership Updates
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo
Live finance-specific insights
First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S. revenue growth accelerated to 14.9%, driven by AtriClip FLEX-Mini®, cryoSPHERE® MAX™, EnCompass® clamp, and AtriClip PRO-Mini® AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. "Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined exe
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricur
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as
Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third quarter and $25.1 million year to date AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results. "Our third quarter results demonstrate strong execution and patient focus across the business. We are
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, October 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, October 29, 2025, to discuss its third quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at
Worldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all 6,500 patients in the ground-breaking LeAAPS trial AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results. "Our stellar results reflect the power of innovation and the
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2025 financial results on Tuesday, July 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, July 29, 2025, to discuss its second quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https:/
Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. "Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business," said Michael Carrel, President and Chief Executiv
This live feed shows all institutional transactions in real time.
SC 13G - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G - AtriCure, Inc. (0001323885) (Subject)